This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Iravani, A Search for Related Content PubMed PubMed Citation Articles by Iravani, A

 Previous Article  |  Next Article 

Antimicrob Agents Chemother. 1991 April; 35(4): 750-752

Loracarbef versus cefaclor in the treatment of urinary tract infections in women.

Department of Pediatrics, College of Medicine, University of Florida, Gainesville 32610-0296.

ABSTRACT

In a double-blind, prospective, randomized study, 108 college women with acute urinary tract infections were treated for 7 days with either loracarbef (LY163892) at 200 mg once daily (n = 53) or cefaclor at 250 mg three times daily (n = 55). The cure rates at 5 to 9 days after treatment in the loracarbef and cefaclor groups were 96 and 90%, respectively. Both loracarbef and cefaclor are safe, well tolerated, and effective in the treatment of urinary tract infections in women.

This article has been cited by other articles:

• Rodman, D. P., McKnight, J. T., Anderson, R. L. (1994). A Critical Review of the New Oral Cephalosporins: Considerations and Place in Therapy. Arch Fam Med 3: 975-980 [Abstract]